Literature DB >> 19285315

Expression of genes encoding matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in normal and diseased canine mitral valves.

H Aupperle1, J Thielebein, B Kiefer, I März, G Dinges, H-A Schoon, A Schubert.   

Abstract

The pathogenesis of canine chronic valvular disease (CVD) is not fully characterized. The present study investigates the expression of genes encoding matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in normal and diseased mitral valves (MVs). Samples from normal (n=15) or diseased (n=10) canine MVs were subject to real-time polymerase chain reaction (PCR) for quantification of mRNA encoding MMP-1, -2, -9 and -14 and TIMP-2, -3 and -4. In normal valves there was low expression of mRNA encoding MMP-2, -9 and -14 and TIMP-3. In the valves from dogs with CVD there was significantly increased transcription of mRNA encoding MMP-1 and -14 and TIMP-2, -3 and -4, but no elevation in mRNA encoding MMP-2 and -9. MMPs and TIMPs are therefore likely to be involved in extracellular matrix metabolism in normal canine MVs and there are significant alterations in the expression of genes encoding these molecules during CVD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285315     DOI: 10.1016/j.jcpa.2009.01.001

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  9 in total

Review 1.  Differentiating the aging of the mitral valve from human and canine myxomatous degeneration.

Authors:  Patrick S Connell; Richard I Han; K Jane Grande-Allen
Journal:  J Vet Cardiol       Date:  2012-02-24       Impact factor: 1.701

Review 2.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.

Authors:  Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Pathol       Date:  2020-01-07       Impact factor: 2.185

3.  Matrix metalloproteinases and their inhibitors in canine mammary tumors.

Authors:  Luca Aresu; Mery Giantin; Emanuela Morello; Marta Vascellari; Massimo Castagnaro; Rosa Lopparelli; Vanessa Zancanella; Anna Granato; Spiridione Garbisa; Arianna Aricò; Alice Bradaschia; Franco Mutinelli; Mauro Dacasto
Journal:  BMC Vet Res       Date:  2011-07-04       Impact factor: 2.741

4.  Plasma proANP and SDMA and microRNAs are associated with chronic mitral regurgitation in a pig model.

Authors:  Susanna Cirera; Sophia G Moesgaard; Nora E Zois; Nathja Ravn; Jens P Goetze; Signe E Cremer; Tom Teerlink; Páll S Leifsson; Jesper L Honge; J Michael Hasenkam; Lisbeth H Olsen
Journal:  Endocr Connect       Date:  2013-09-24       Impact factor: 3.335

5.  The transcriptomic profile of peripheral blood nuclear cells in dogs with heart failure.

Authors:  Magdalena Hulanicka; Magdalena Garncarz; Marta Parzeniecka-Jaworska; Michał Jank
Journal:  BMC Genomics       Date:  2014-06-21       Impact factor: 3.969

6.  Severity of Mitral Valve Degeneration Is Associated with Chromosome 15 Loci in Whippet Dogs.

Authors:  Joshua A Stern; Weihow Hsue; Kun-Ho Song; Eric S Ontiveros; Virginia Luis Fuentes; Rebecca L Stepien
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

Review 7.  Comparative Transcriptomic Profiling and Gene Expression for Myxomatous Mitral Valve Disease in the Dog and Human.

Authors:  Greg R Markby; Kim M Summers; Vicky E MacRae; Brendan M Corcoran
Journal:  Vet Sci       Date:  2017-07-17

8.  Association of matrix metalloprotease 1, 3, and 12 polymorphisms with rheumatic heart disease in a Chinese Han population.

Authors:  Wei Hu; Yujia Ye; Yirui Yin; Peng Sang; Linhua Li; Jing Wang; Wen Wan; Rui Li; Xiangfeng Bai; Yuehui Xie; Zhaohui Meng
Journal:  BMC Med Genet       Date:  2018-02-20       Impact factor: 2.103

9.  Fluoroquinolones and Aortic Diseases: Is There a Connection.

Authors:  Davide Carino; Mohammad A Zafar; Mrinal Singh; Bulat A Ziganshin; John A Elefteriades
Journal:  Aorta (Stamford)       Date:  2019-09-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.